|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
EP2292264A3
(en)
|
2003-07-24 |
2012-12-19 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
|
WO2005105849A1
(en)
*
|
2004-04-30 |
2005-11-10 |
Innate Pharma |
Compositions and methods for treating proliferative disorders such as nk-type ldgl
|
|
KR101299167B1
(ko)
*
|
2004-07-01 |
2013-08-30 |
노보 노르디스크 에이/에스 |
인간 항-ｋｉｒ 항체
|
|
DK2287195T3
(da)
|
2004-07-01 |
2019-08-19 |
Innate Pharma |
Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
|
|
EP2801583B1
(en)
|
2004-07-10 |
2018-04-25 |
Fox Chase Cancer Center |
Genetically modified human natural killer cell lines
|
|
US20090104170A1
(en)
*
|
2004-11-02 |
2009-04-23 |
Richard William Wyatt Childs |
Compositions and methods for treating hyperproliferative disorders
|
|
SI1836225T1
(sl)
|
2005-01-06 |
2012-06-29 |
Novo Nordisk As |
Kir vezujoäśa sredstva in postopki za njihovo rabo
|
|
WO2006072625A2
(en)
|
2005-01-06 |
2006-07-13 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
|
SI1835937T1
(sl)
|
2005-01-06 |
2012-08-31 |
Novo Nordisk As |
Sestavki in postopki za zdravljenje virusne infekcije
|
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
JP5419067B2
(ja)
*
|
2005-10-14 |
2014-02-19 |
イナート・ファルマ・ソシエテ・アノニム |
増殖性障害を処置するための組成物および方法
|
|
CN101578113B
(zh)
*
|
2007-01-11 |
2015-04-22 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
EP2808402A3
(en)
*
|
2008-12-29 |
2015-03-25 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Methods of predicting responsiveness to interferon treatment
|
|
EP2535052B1
(en)
*
|
2010-02-08 |
2016-09-07 |
Biotherapy Institute Of Japan |
Method for producing nk cell enhancement-type blood product
|
|
CA2818684C
(en)
|
2010-11-22 |
2023-02-21 |
Innate Pharma Sa |
Nk cell modulating treatments and methods for treatment of hematological malignancies
|
|
TWI560200B
(en)
*
|
2011-05-25 |
2016-12-01 |
Innate Pharma Sa |
Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
|
|
US20140234342A1
(en)
|
2011-06-21 |
2014-08-21 |
Innate Pharma |
Nkp46-mediated nk cell tuning
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
RU2017127486A
(ru)
*
|
2011-11-23 |
2019-02-06 |
Ф. Хоффманн-Ля Рош Аг |
Клетки млекопитающих, экспрессирующие лиганд cd40l, и их применение
|
|
CN104640880B
(zh)
*
|
2012-09-19 |
2020-06-09 |
先天制药公司 |
Kir3dl2结合剂
|
|
KR102130865B1
(ko)
|
2012-10-02 |
2020-08-05 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물
|
|
ES2707057T3
(es)
|
2013-11-06 |
2019-04-02 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
|
|
EP3187583B1
(en)
*
|
2014-08-29 |
2023-04-26 |
National University Corporation Hokkaido University |
Monoclonal antibody against kir2ds1
|
|
US11639384B2
(en)
|
2014-10-28 |
2023-05-02 |
University Children's Hospital Tübingen |
Treatment of pediatric BCP-ALL patients with an anti-KIR antibody
|
|
CN113713091A
(zh)
|
2015-02-06 |
2021-11-30 |
新加坡国立大学 |
工程免疫细胞及其用途和生产方法
|
|
SG11201708223QA
(en)
|
2015-04-17 |
2017-11-29 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
PL3291679T3
(pl)
|
2015-05-06 |
2022-04-25 |
Snipr Technologies Limited |
Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty
|
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
CN107921087A
(zh)
|
2015-07-16 |
2018-04-17 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
SMT202200118T1
(it)
*
|
2015-11-03 |
2022-05-12 |
Janssen Biotech Inc |
Anticorpi che legano specificamente pd-1 e loro usi
|
|
KR20180104597A
(ko)
|
2015-11-07 |
2018-09-21 |
멀티비르 인코포레이티드 |
암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
LT3458053T
(lt)
|
2016-05-20 |
2022-02-25 |
Biohaven Pharmaceutical Holding Company Ltd. |
Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
EP3484516A4
(en)
|
2016-07-14 |
2020-03-18 |
Fred Hutchinson Cancer Research Center |
MULTIPLE SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOP BINDING FOR TREATING CANCER
|
|
BR112019006041A2
(pt)
|
2016-09-27 |
2019-09-03 |
Board Of Regents, The University Of Texas System |
métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
|
|
GB201616365D0
(en)
*
|
2016-09-27 |
2016-11-09 |
Helsingin Yliopisto |
Non-genetic modification of enveloped viruses
|
|
WO2018071668A1
(en)
|
2016-10-12 |
2018-04-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions for tusc2 immunotherapy
|
|
WO2018073363A1
(en)
|
2016-10-21 |
2018-04-26 |
Innate Pharma |
Treatment with anti-kir3dl2 agents
|
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
|
IL269026B2
(en)
|
2017-03-31 |
2024-12-01 |
Bristol Myers Squibb Co |
Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients
|
|
JP6933724B2
(ja)
|
2017-04-05 |
2021-09-08 |
コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ |
Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物
|
|
BR112019023855B1
(pt)
|
2017-05-12 |
2021-11-30 |
Harpoon Therapeutics, Inc |
Proteínas de ligação à mesotelina
|
|
US12116406B2
(en)
|
2017-05-26 |
2024-10-15 |
Fred Hutchinson Cancer Center |
Anti-CD33 antibodies and uses thereof
|
|
CN107261304A
(zh)
*
|
2017-06-05 |
2017-10-20 |
中国兽医药品监察所 |
一种奶牛的布鲁氏菌病免疫试剂盒及其应用
|
|
US11648269B2
(en)
|
2017-08-10 |
2023-05-16 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
|
|
JP7084990B2
(ja)
|
2017-10-13 |
2022-06-15 |
ハープーン セラピューティクス，インク． |
三重特異性タンパク質と使用方法
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
CN108060137B
(zh)
*
|
2017-12-26 |
2021-07-02 |
博生吉医药科技(苏州)有限公司 |
Il7和il21修饰的nk92细胞、制备方法及其应用
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
AU2019218125B2
(en)
|
2018-02-08 |
2025-03-13 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
PE20220278A1
(es)
|
2018-02-08 |
2022-02-25 |
Dragonfly Therapeutics Inc |
Dominios variables de anticuerpos que se dirigen al receptor nkg2d
|
|
TW201942134A
(zh)
|
2018-02-20 |
2019-11-01 |
美商蜻蜓醫療公司 |
結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
|
|
US12454561B2
(en)
|
2018-03-19 |
2025-10-28 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
BR112020018539A2
(pt)
|
2018-03-23 |
2020-12-29 |
Bristol-Myers Squibb Company |
Anticorpos contra mica e/ou micb e usos dos mesmos
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
WO2019185551A1
(en)
|
2018-03-25 |
2019-10-03 |
Snipr Biome Aps. |
Treating & preventing microbial infections
|
|
KR20200139724A
(ko)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
SG11202010996QA
(en)
|
2018-05-23 |
2020-12-30 |
Nat Univ Singapore |
Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
EA202190468A1
(ru)
|
2018-08-08 |
2021-07-06 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
KR20250112921A
(ko)
|
2018-08-08 |
2025-07-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EP3849565A4
(en)
|
2018-09-12 |
2022-12-28 |
Fred Hutchinson Cancer Research Center |
REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
EP3947715A4
(en)
|
2018-11-21 |
2022-11-23 |
Board of Regents, The University of Texas System |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
|
MX2021007271A
(es)
|
2018-12-21 |
2021-07-15 |
Onxeo |
Nuevas moleculas de acido nucleico conjugado y sus usos.
|
|
CN114174537A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
细胞定位特征和组合疗法
|
|
WO2020243563A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures for suitability to immuno-oncology therapy
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
CN111424012A
(zh)
*
|
2020-03-30 |
2020-07-17 |
威海市中心医院 |
一种nk细胞培养用的饲养细胞去增殖能力的处理方法
|
|
EP4146271A4
(en)
|
2020-05-06 |
2024-09-04 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
US20250262293A1
(en)
|
2020-07-07 |
2025-08-21 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
IL300916A
(en)
|
2020-08-31 |
2023-04-01 |
Bristol Myers Squibb Co |
Cell localization signature and immunotherapy
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
US20240000837A1
(en)
*
|
2020-12-23 |
2024-01-04 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies
|
|
WO2022146947A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
MX2023007650A
(es)
|
2020-12-28 |
2023-09-11 |
Bristol Myers Squibb Co |
Metodos de tratamiento de tumores.
|
|
AU2022218137A1
(en)
|
2021-02-03 |
2023-08-24 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
US12377144B2
(en)
|
2021-03-03 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
MX2024000674A
(es)
|
2021-07-13 |
2024-02-07 |
BioNTech SE |
Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
|
|
CN118055840A
(zh)
|
2021-10-08 |
2024-05-17 |
3M创新有限公司 |
具有调节的刚度、减小的拉延区和力预算的狭缝模组件
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
US20250051440A1
(en)
|
2021-12-14 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
|
US20240294926A1
(en)
|
2021-12-16 |
2024-09-05 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
EP4531916A1
(en)
|
2022-06-02 |
2025-04-09 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024026385A1
(en)
*
|
2022-07-28 |
2024-02-01 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies
|
|
JPWO2024090458A1
(enExample)
*
|
2022-10-25 |
2024-05-02 |
|
|
|
IL321098A
(en)
|
2022-12-14 |
2025-07-01 |
Astellas Pharma Europe Bv |
Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
|
|
CN121712571A
(zh)
|
2023-08-15 |
2026-03-20 |
百时美施贵宝公司 |
陶瓷羟基磷灰石色谱流通法
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
TW202541837A
(zh)
|
2023-12-08 |
2025-11-01 |
日商安斯泰來製藥公司 |
含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
CN117883553B
(zh)
*
|
2024-01-12 |
2024-08-27 |
成都医学院 |
Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用
|